Literature DB >> 999735

The lupus anticoagulant.

M Boxer, L Ellman, A Carvalho.   

Abstract

The clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. The anti-coagulant is thought to act by blocking the activation of prothrombin by the prothrombin activator comlex of factors Xa, V, and phospholipid. Although the anticoagulant has been principally associated with diseases of immune origin, 14 of the present patients had disorders not thought to be immune in nature. Eighteen patients underwent twenty-one operative procedures with only a single episode of excessive bleeding. In the author's experience, the lupus anticoagulant is a rare cause of bleeding.

Entities:  

Mesh:

Year:  1976        PMID: 999735     DOI: 10.1002/art.1780190603

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  18 in total

Review 1.  Drug-induced lupus anticoagulants and antiphospholipid antibodies.

Authors:  Jeffrey S Dlott; Robert A S Roubey
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

2.  Circulating lupus type anticoagulant and pulmonary hypertension associated with mixed connective tissue disease.

Authors:  P Hainaut; E Lavenne; J M Magy; E G Lebacq
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

3.  Budd-Chiari syndrome as the major thrombotic complication of systemic lupus erythematosus with the lupus anticoagulant.

Authors:  M Averbuch; Y Levo
Journal:  Ann Rheum Dis       Date:  1986-05       Impact factor: 19.103

Review 4.  Systemic lupus erythematosus clinical issues.

Authors:  M B Stevens
Journal:  Springer Semin Immunopathol       Date:  1986

Review 5.  Lupus anticoagulant associated syndrome in benign and malignant systemic disease.

Authors:  U Dührsen; D Paar; G Brittinger
Journal:  Klin Wochenschr       Date:  1987-09-01

6.  Prevalence of antinuclear antibodies in patients with habitual abortion and in normal and toxemic pregnancies.

Authors:  I Garcia-De La Torre; L Hernandez-Vazquez; J Angulo-Vazquez; A Romero-Ornelas
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

7.  The lupus anticoagulant, pulmonary thromboembolism, and fatal pulmonary hypertension.

Authors:  N E Anderson; M R Ali
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

8.  Widespread cutaneous necrosis associated with antiphospholipid syndrome.

Authors:  I M Jou; M F Liu; S C Chao
Journal:  Clin Rheumatol       Date:  1996-07       Impact factor: 2.980

9.  Transient lupus anticoagulant associated with hypoprothrombinemia and factor XII deficiency following adenovirus infection.

Authors:  U Jaeger; S Kapiotis; I Pabinger; E Puchhammer; P A Kyrle; K Lechner
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

10.  Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

Authors:  R H Derksen; P Hasselaar; L Blokzijl; F H Gmelig Meyling; P G De Groot
Journal:  Ann Rheum Dis       Date:  1988-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.